Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Investig Drugs. 2003 Jun;4(6):757-63.

BAY-43-9006 Bayer/Onyx.

Author information

  • 1Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, East Fifth Street, Greenville, NC 27858-4553, USA.

Abstract

Bayer and Onyx are developing BAY-43-9006, an oral cytostatic Raf kinase inhibitor for the potential treatment of colorectal and breast cancers, hepatocellular carcinoma and non-small-cell lung cancer, in addition to acute myelogenous leukemia, myelodysplastic syndrome and other cancers. A US IND was filed in May 2000 and by February 2003 BAY-43-9006 was in phase II trials, with phase III trials expected to begin later in 2003.

PMID:
12901237
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk